Collectively, our results suggest that CRISPR/Cas9 genome editing targeting the TGFBI gene in human ABCG2+/ABCB5+ double-positive LESCs may be applied therapeutically in corneal dystrophy patients. Here, ABCG2 is linked to corneal dystrophy.